Expert Interviews

Thomas Martens, M.D., explains what drives adoption and how CONNECT's Level A evidence could move CGM coverage.

This segment introduces the Phase III CROWN study, providing essential background on its design and framing the remarkable significance of reporting 7-year follow-up data in the setting of advanced, stage 4 ALK-positive NSCLC.

This segment introduces the Phase III CROWN study, providing essential background on its design and framing the remarkable significance of reporting 7-year follow-up data in the setting of advanced, stage 4 ALK-positive NSCLC.

Thomas Martens, M.D., on why outcomes with CGM in CONNECT—including five more hours per day in range—came largely from lifestyle change, not added medication.

Thomas Martens, M.D., explains why CONNECT's 1.6% A1C reduction with continuous glucose monitoring is so exciting in patients with type 2 diabetes not on insulin.

Evolocumab cut major cardiac events by 29% in high-risk diabetes without prior heart attack or stroke in VESALIUS-CV subgroup data from ADA 2026.

Survodutide's SYNCHRONIZE trials show weight loss driven by visceral and liver fat, not muscle.

This segment dives into two of the most practically important questions facing clinicians who manage ALK-positive NSCLC: how to optimally test for ALK rearrangements, and how to select among the growing number of first-line treatment options available today.

This segment opens with foundational context on ALK-positive non-small cell lung cancer, establishing the clinical and scientific backdrop that makes this disease state — and its recent treatment advances — so compelling.

Phase 3 data show survodutide reduced liver fat by 63% and visceral fat by 34% — effects investigators say go beyond what weight loss alone explains.

Shame, fueled by stigma, can deter care for HIV patients; recognizing it and responding compassionately can reduce harm, according to Abigail Bachelder, M.P.H., Ph.D., associate psychiatry professor at Boston University Chobanian & Avedisian School of Medicine.

Tanya Dorff, M.D., breaks down early ABBV-969 data showing strong responses in heavily pretreated mCRPC at ASCO 2026.

A study participant in the trial of daraxonrasib felt like he was part of something special, says UT MD Anderson's Subam Pant, "and he is."

In the final episode, ‘The Future Landscape: Topical vs. Systemic JAK Inhibitors in Vitiligo ,’ the panelists explored the following critical questions:

The second-line drug for metastatic pancreatic cancer is pan-RAS inhibitor that recruits cyclophilin A to stick to RAS proteins, explains Subham Pant, M.D., M.B.B.S., of The University of Texas MD Anderson Cancer Center.

In an interview before the annual ASCO meeting, Eduardo Vilar-Sanchez, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, talks about NOUS-209, an immunotherapy being studied to prevent cancer in those with Lynch syndrome mutations.

Eduardo Vilar-Sanchez, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, was awarded for his work in cancer immunoprevention and his efforts to develop a cancer vaccine for those who are carriers of Lynch mutations.

Treatment after treatment for second-line treatment for pancreatic cancer has failed in clinical trials. Daraxonrasib seems to have broken the losing streak, says MD Anderson's Shubman Pant, M.D., M.B.B.S.

Lead ARACOG trial investigator Alicia Morgans, M.D., discusses the importance of including cognitive effects in the conversation around prostate cancer treatment.

A new investigational combination therapy for advanced KRAS G12C-mutant non-small cell lung cancer showed "highly promising" results with “manageable” side effects, according to the study’s lead author.

Ferdinandos Skoulidis, M.D., Ph.D., explains what’s next for this treatment for patients with previously untreated advanced or metastatic KRAS G12C-mutated non-small cell lung cancer.

Divarasib plus pembrolizumab shows strong responses in patients with advanced KRAS G12C+ non-small cell lung cancer, according to the results of the Krascendo 170 study, presented today at ASCO 2026.

Dana-Farber’s Katherine Janeway, M.D., discusses how reimbursement policies for molecular diagnostics have failed to keep pace with scientific evidence, leaving gaps in the care for pediatric bone cancer patients.

Dana-Farber’s Katherine Janeway, M.D., discusses how molecular biomarkers inform treatment decisions in children and adolescents with the bone cancers Ewing sarcoma and osteosarcoma.

Bispecific antibodies are a major advance in multiple myeloma treatment with outstanding efficacy, with many clinical trials underway that are providing the evidence for using them in earlier lines of treatments.

Health systems and clinics need to work together to manage care of the potentially dangerous side effects of bispecific antibodies during the early, step-up phase of treatment, Adams said. Those side effects include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.

In ‘A Milestone in Vitiligo: Clinical Efficacy and Long-Term Repigmentation Trends,’ the expert dermatologist examined the following critical questions:

Adams said she has seen firsthand the difference that bispecific antibodies have made. “Patients that would have never gotten into remission are getting into remission. Patients that would have never seen the birth of their grandchild are now seeing the birth of their grandchild,” Adams said. Some real-world data are showing slightly reduced efficacy that was seen in clinical trials, Adams said. There is a need for research that would develop comparator data to other therapies, she noted.